Research and Development collaborations

GenOdyssee uses its unique intellectual property position to propose research and development collaborations, access to its unique technology and integrated drug discovery process, for the discovery of new generation protein drugs applicable to a broad variety of medical disorders. GenOdyssee’s technology is applicable to virtually all human protein drugs, except antibodies. This includes cytokines and growth factors - including interferons, erythropoietins, interleukins, and soluble receptors – clotting factors, insulin, and hormones.

First Pharma partner: Baxter International (BAX) subsidiary Baxter AG in the discovery of novel blood clotting factors
GO_Press_Release_Oct23_2006 PDF

Product development collaborations

GenOdyssee is developing numerous contacts with CMOs, innovative drug delivery technology companies, as well as biotech and pharma companies, in Europe and in the USA as well as in emerging countries, for the development of some of its lead products in its portfolio of innovative protein therapeutic variants. The company’s primary focus is in the development of innovative treatments in the following therapeutic areas: immunotherapy, infectious diseases, and hematology.

Lead products available for partnership are:

GEA007.1 PDF
Mechanism of action: anti-infective
Therapeutic indications: 1st Hepatitis C (HCV genotype 1-infected patients)
Others: DNA and other RNA virus infections

GEA009.2 PDF
Mechanism of action: innate and adaptive immunity responses stimulating agent
Therapeutic indications: 1st Immunotherapy of cancer
Others: adjuvant to vaccines, immunotherapy of certain chronic viral infections (Hep C, AIDS)

GO-EPO PDF
Mechanism of action: CFU-E progenitor cell-stimulating agent
Therapeutic indications: 1st renal disease-related anemia
Others: pre-dialysis, cancer-related anemia

GenOdyssee’s strategic plans forecast the development at some point of at least one lead product until proof of concept in man (Phase I/II), at the company’s own expenses.